ADL5859

ADL5859 is a novel, orally bioavailable small molecule developed as a selective delta opioid receptor agonist for the management of pain. Unlike traditional opioids that activate multiple opioid receptors (mu, delta, and kappa), ADL5859 selectively targets the delta opioid receptor, which was hypothesized to provide analgesic effects with fewer side effects such as respiratory depression, sedation, and euphoria. The drug demonstrated oral activity and efficacy in preclinical models and early clinical trials for various pain conditions including neuropathic pain, osteoarthritis-related pain, inflammatory pain, and dental pain. Despite initial promise and completion of several phase II trials, further development was discontinued after studies failed to show significant efficacy over placebo[1][3][4][5][6][7].

Other names

compound 20compound20compound-20